Rein Therapeutics (RNTX) Earnings Analysis
Rein Therapeutics (RNTX) next reports earnings on 2026-08-13, consensus EPS -0.17 USD. Last quarter (2026-05-15) it beat with EPS -0.19 USD vs -0.49 USD est (+61.2%). It has beaten estimates in 3/8 recent quarters (38%). Trailing P/E -0.44.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RNTX next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.17 USD |
| Revenue estimate | n/a |
RNTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.19 USD | -0.49 USD | +61.2% | Beat |
| 2026-03-26 | -1.09 USD | -1.09 USD | 0% | Beat |
| 2025-11-14 | -0.21 USD | -0.24 USD | +12.5% | Beat |
| 2025-08-14 | -0.28 USD | -0.22 USD | -27.3% | Miss |
| 2025-04-07 | -0.26 USD | -0.14 USD | -85.7% | Miss |
| 2024-12-31 | -1.88913 USD | -0.46 USD | -310.7% | Miss |
| 2024-11-14 | -0.27 USD | -0.25 USD | -8% | Miss |
| 2024-08-14 | -0.45 USD | -0.25 USD | -80% | Miss |
Beat rate: 3/8 (38%) over reported quarters with consensus data.
RNTX valuation and analyst view
| Trailing P/E | -0.44 |
|---|---|
| Trailing EPS | -1.65405 USD |
| Price / book | 2.20 |
| Dividend yield | 0.00% |
| Market cap | 0.02B |
| Analyst consensus | Buy (1 buy / 1 hold / 0 sell) |
| Avg price target | 6 USD |
Related research pages
Frequently asked questions
When is Rein Therapeutics (RNTX)'s next earnings date?
Rein Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.17 USD.
Did RNTX beat earnings last quarter?
In its 2026-05-15 report, RNTX posted EPS of -0.19 USD versus a -0.49 USD estimate — a beat of 61.2%.
What is RNTX's earnings track record?
Over the last 8 reported quarters with consensus data, RNTX beat estimates 3 times (38%).
What is RNTX's current P/E ratio and EPS?
RNTX trades at a trailing P/E of -0.44 on trailing EPS of -1.6540465781071347 USD.
What do analysts rate RNTX?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 6 USD.